Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | 29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC

Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses 29-month follow-up data from the Phase III CheckMate 648 trial (NCT0314315) of first-line nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (ESCC). A total of 970 patients were randomized and initial results demonstrated the superiority of incorporating nivolumab over chemotherapy alone. A longer follow-up additionally shows robust duration of survival in patients receiving nivolumab with ipilimumab and no changes in the safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

As you know the result of the CheckMate 648 was already published in the New England Journal of Medicine. This shows superiority of the nivo-chemo and the nivo-ipi over chemotherapy alone in patients with esophageal squamous cell carcinoma.

After the follow-up of the 29 months, the consistent superiority of the nivo-chemo and the nivo-ipi was observed over chemotherapy alone. The difference is the long-term follow-up result does slightly improved the hazard ratio of the OS was seen in the nivo-ipi arm compared to the primary result...

As you know the result of the CheckMate 648 was already published in the New England Journal of Medicine. This shows superiority of the nivo-chemo and the nivo-ipi over chemotherapy alone in patients with esophageal squamous cell carcinoma.

After the follow-up of the 29 months, the consistent superiority of the nivo-chemo and the nivo-ipi was observed over chemotherapy alone. The difference is the long-term follow-up result does slightly improved the hazard ratio of the OS was seen in the nivo-ipi arm compared to the primary result.

So that mean that duration of the response was more seen in the ipi-nivo arm. And indeed no safety profile was changing and no new signal of the immune-related toxicity was seen even after the longer follow-up time.

Read more...